TRTimothy James Russell

Timothy James Russell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Timothy James Russell has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Manuel Llinás

    Pennsylvania State University

    4 shared publications
  • C. Denise Okafor

    Affiliations Department of Biochemistry and Molecular Biology, Pennsylvania State University, State College, Pennsylvania, United States of America, Department of Chemistry, Pennsylvania State University, State College, Pennsylvania, United States of America

    2 shared publications
  • Erandi K. De Silva

    Affiliation Lewis-Singler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey, United States of America

    2 shared publications
  • Francisco-Javier Gamo

    Affiliation Global Health Medicines, GlaxoSmithKline, Tres Cantos, Spain

    2 shared publications
  • Gabrielle Josling

    Affiliations Department of Biochemistry and Molecular Biology, Pennsylvania State University, State College, Pennsylvania, United States of America, Huck Institutes Center for Malaria Research (CMaR), Pennsylvania State University, State College, Pennsylvania, United States of America, Huck Institutes Center for Infectious Disease Dynamics, Pennsylvania State University, State College, Pennsylvania, United States of America

    2 shared publications
  • Gianni Panagiotou

    Affiliations Systems Biology and Bioinformatics, Leibniz Institute for Natural Products Research and Infection Biology, Hans Knöll Institute, Jena, Germany, Department of Medicine, the University of Hong Kong, Hong Kong SAR, China

    2 shared publications

Latest Publications

  • Open Access

    Inhibitors of ApiAP2 protein DNA binding exhibit multistage activity against Plasmodium parasites

    by Timothy James Russell, Erandi K. De Silva, Valerie M. Crowley, Kathryn Shaw-Saliba, Namita Dube, Gabrielle Josling, Charisse Flerida A. Pasaje, Irene Kouskoumvekaki, Gianni Panagiotou, Jacquin C. Niles, et al.

    Plasmodiumparasites are reliant on the Apicomplexan AP2 (ApiAP2) transcription factor family to regulate gene expression programs. AP2 DNA binding domains have no homologs in the human or mosquito host genomes, making them potential antimalarial drug targets. Using anin-silicoscreen to dock thousands of small molecules into the crystal structure of the AP2-EXP (Pf3D7_1466400) AP2 domain (PDB:3IGM), we identified putative AP2-EXP interacting compounds. Four compounds were found to block DNA binding by AP2-EXP and at least one additional ApiAP2 protein. Our top ApiAP2 competitor compound perturbs the transcriptome ofP.falciparumtrophozoites and results in a decrease in abundance of log2fold change > 2 for 50% (46/93) of AP2-EXP target genes. Additionally, two ApiAP2 competitor compounds have multi-stage anti-Plasmodiumactivity against blood and mosquito stage parasites. In summary, we describe a novel set of antimalarial compounds that interact with AP2 DNA binding domains. These compounds may be used for future chemical genetic interrogation of ApiAP2 proteins or serve as starting points for a new class of antimalarial therapeutics.


  • Open Access

    Identification of Antimalarial Compounds that Inhibit Apicomplexan AP2 Proteins in the Human Malaria Parasite Plasmodium falciparum

    by Timothy Russell, Erandi K. De Silva, Valerie Crowley, Kathryn Shaw-Saliba, Namita Dube, Gabrielle Josling, Charisse Flerida A. Pasaje, Irene Kouskoumvekaki, Gianni Panagiotou, Jacquin C. Niles, et al.

    Plasmodium parasites are reliant on the Apicomplexan AP2 (ApiAP2) transcription factor family to regulate gene expression programs. AP2 DNA binding domains have no homologs in the human or mosquito host genomes, making them potential antimalarial drug targets. Using an in-silico screen to dock thousands of small molecules into the crystal structure of the AP2-EXP (Pf3D7_1466400) AP2 domain (PDB:3IGM), we identified compounds that interact with this domain. Four compounds were found to compete for DNA binding with AP2-EXP and at least one additional ApiAP2 protein. Our top ApiAP2 competitor compound perturbs the transcriptome of P. falciparum trophozoites and results in a decrease in abundance of log 2 fold change > 2 for 50% (46/93) of AP2-EXP target genes. Additionally, two ApiAP2 competitor compounds have multi-stage anti- Plasmodium activity against blood and mosquito stage parasites. In summary, we describe a novel set of antimalarial compounds that are targeted against the ApiAP2 family of proteins. These compounds may be used for future chemical genetic interrogation of ApiAP2 proteins or serve as starting points for a new class of antimalarial therapeutics. Author Summary: Plasmodium parasites are the causative agent of malaria, which resulted in over 600,000 deaths in 2021. Due to resistance arising for every antimalarial therapeutic deployed to date, new drug targets and druggable pathways must be explored. To address this concern, we used a molecular docking screen to predict competitors of DNA binding by the parasite specific family of Apicomplexan AP2 (ApiAP2) transcription factor proteins for testing in vitro and in vivo . We find that ApiAP2 competing compounds have antimalarial activity consistent with the disruption of gene regulation. This work will further our understanding of both the biological role and targetability of parasite transcriptional regulation.


  • A heat-shock response regulated by the PfAP2-HS transcription factor protects human malaria parasites from febrile temperatures

    by Elisabet Tintó-Font, Lucas Michel-Todó, Timothy J. Russell, Núria Casas-Vila, David J. Conway, Zbynek Bozdech, Manuel Llinás, Alfred Cortés

    Periodic fever is a characteristic clinical feature of human malaria, but how parasites survive febrile episodes is not known. Although the genomes of Plasmodium species encode a full set of chaperones, they lack the conserved eukaryotic transcription factor HSF1, which activates the expression of chaperones following heat shock. Here, we show that PfAP2-HS, a transcription factor in the ApiAP2 family, regulates the protective heat-shock response in Plasmodium falciparum. PfAP2-HS activates the transcription of hsp70-1 and hsp90 at elevated temperatures. The main binding site of PfAP2-HS in the entire genome coincides with a tandem G-box DNA motif in the hsp70-1 promoter. Engineered parasites lacking PfAP2-HS have reduced heat-shock survival and severe growth defects at 37 °C but not at 35 °C. Parasites lacking PfAP2-HS also have increased sensitivity to imbalances in protein homeostasis (proteostasis) produced by artemisinin, the frontline antimalarial drug, or the proteasome inhibitor epoxomicin. We propose that PfAP2-HS contributes to the maintenance of proteostasis under basal conditions and upregulates specific chaperone-encoding genes at febrile temperatures to protect the parasite against protein damage.


  • Top Cited Papers
    Open Access

    Dissecting the role of PfAP2-G in malaria gametocytogenesis

    by Gabrielle A. Josling, Timothy J. Russell, Jarrett Venezia, Lindsey Orchard, Riëtte van Biljon, Heather J. Painter, Manuel Llinás

    In the malaria parasite Plasmodium falciparum, the switch from asexual multiplication to sexual differentiation into gametocytes is essential for transmission to mosquitos. The transcription factor PfAP2-G is a key determinant of sexual commitment that orchestrates this crucial cell fate decision. Here we identify the direct targets of PfAP2-G and demonstrate that it dynamically binds hundreds of sites across the genome. We find that PfAP2-G is a transcriptional activator of early gametocyte genes, and identify differences in PfAP2-G occupancy between gametocytes derived via next-cycle and same-cycle conversion. Our data implicate PfAP2-G not only as a transcriptional activator of gametocyte genes, but also as a potential regulator of genes important for red blood cell invasion. We also find that regulation by PfAP2-G requires interaction with a second transcription factor, PfAP2-I. These results clarify the functional role of PfAP2-G during sexual commitment and early gametocytogenesis.